secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-09-05T23:59:59+00:00
Accession:  0001493152-25-012740
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine to Present at H.C. Wainwright Conference Sept 8-10, 2025
-----------------------------------------------------------------

- Company management will present and hold 1x1 meetings at H.C. Wainwright 27th Annual Global Investment Conference in New York.
- Conference runs September 8-10, 2025; presentation available from 7:00 a.m. EDT on Sept 5.
- Lipocine's pipeline includes LPCN 1154 (postpartum depression), LPCN 2101 (epilepsy), LPCN 2203 (essential tremor), and others.
- TLANDO (testosterone undecanoate) is FDA-approved for hypogonadism; company exploring partnerships for several candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225012740/0001493152-25-012740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225012740/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-012740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer